NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CKPT Stock Alerts $1.46 +0.04 (+2.82%) (As of 10:29 AM ET) Add Compare Share Share Today's Range$1.42▼$1.4650-Day Range$1.44▼$2.3252-Week Range$1.30▼$3.62Volume35,598 shsAverage Volume526,548 shsMarket Capitalization$52.11 millionP/E RatioN/ADividend YieldN/APrice Target$22.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Checkpoint Therapeutics alerts: Email Address Checkpoint Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,447.9% Upside$22.60 Price TargetShort InterestBearish12.35% of Float Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment0.08Based on 8 Articles This WeekInsider TradingSelling Shares$48,297 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.14 out of 5 starsMedical Sector339th out of 908 stocksPharmaceutical Preparations Industry151st out of 424 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.35% of the float of Checkpoint Therapeutics has been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Checkpoint Therapeutics has recently increased by 1.07%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 1.7 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for CKPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,297.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Checkpoint Therapeutics Stock (NASDAQ:CKPT)Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CKPT Stock News HeadlinesApril 24, 2024 | msn.comDUI Checkpoint to be held in Raleigh CountyApril 23, 2024 | businesswire.comCKPT Shareholders With Large Losses Should Contact Robbins LLP for Information About the Checkpoint Therapeutics, Inc. Class ActionApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 23, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointApril 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTApril 19, 2024 | stockhouse.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)April 19, 2024 | prnewswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 18, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)April 17, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmApril 17, 2024 | tmcnet.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) InvestorsApril 16, 2024 | msn.comPSP: Results from April 5 Sobriety CheckpointApril 16, 2024 | stockhouse.comCKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors Can Join the Class Action LawsuitApril 16, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) InvestorsApril 15, 2024 | prnewswire.comCKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!April 15, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) InvestorsApril 14, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointApril 12, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTApril 12, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPTApril 12, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the FirmApril 12, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of InvestorsApril 12, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of InvestorsApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPTApril 12, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointApril 11, 2024 | businesswire.comCheckpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class ActionApril 10, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointSee More Headlines Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$22.60 High Stock Price Target$47.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,491.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,850,000.00 Net Margins-50,336.89% Pretax Margin-50,336.89% Return on EquityN/A Return on Assets-950.01% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual Sales$100,000.00 Price / Sales506.80 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-3.02Miscellaneous Outstanding Shares35,690,000Free Float34,937,000Market Cap$50.68 million OptionableOptionable Beta0.99 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. James F. Oliviero III (Age 48)C.F.A., President, CEO & Director Comp: $921.59kMr. William Garrett Gray (Age 37)CFO, Corporate Secretary & Treasurer Comp: $409.12kKey CompetitorsBioLineRxNASDAQ:BLRXCalciMedicaNASDAQ:CALCEledon PharmaceuticalsNASDAQ:ELDNHomology MedicinesNASDAQ:FIXXImmuneeringNASDAQ:IMRXView All CompetitorsInsiders & InstitutionsLindbrook Capital LLCBought 30,000 shares on 4/25/2024Ownership: 0.084%B. Riley Wealth Advisors Inc.Bought 114,200 shares on 3/15/2024Ownership: 0.694%James F Oliviero IIISold 5,894 sharesTotal: $12,141.64 ($2.06/share)William Garrett GraySold 2,035 sharesTotal: $4,212.45 ($2.07/share)Armistice Capital LLCBought 362,000 shares on 2/13/2024Ownership: 10.310%View All Insider TransactionsView All Institutional Transactions CKPT Stock Analysis - Frequently Asked Questions Should I buy or sell Checkpoint Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks. What is Checkpoint Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 1-year target prices for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they expect the company's share price to reach $22.60 in the next year. This suggests a possible upside of 1,447.9% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts. How have CKPT shares performed in 2024? Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of 2024. Since then, CKPT stock has decreased by 36.2% and is now trading at $1.46. View the best growth stocks for 2024 here. When is Checkpoint Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CKPT earnings forecast. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its quarterly earnings results on Friday, March, 22nd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.36. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million. When did Checkpoint Therapeutics' stock split? Checkpoint Therapeutics's stock reverse split on the morning of Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL). Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lindbrook Capital LLC (0.08%). Insiders that own company stock include James F Oliviero III and William Garrett Gray. View institutional ownership trends. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CKPT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
